Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mobile Platform Offers Patients Ultrafast Genetic Diagnosis

By LabMedica International staff writers
Posted on 01 Jan 2024

Molecular diagnostics traditionally requires knowledge of handling complex equipment and sample preparation. More...

Now, a simple mobile platform for genetic diagnostics that is currently under development can be handled by healthcare professionals without any laboratory training.

Genomtec SA (Wrocław, Poland) is developing its flagship technological solution named Genomtec ID platform which will offer patients ultrafast mobile genetic diagnosis. The Genomtec ID platform is designed to facilitate diagnostic procedures on-site, including locations like public clinics, consulting rooms, hospitals, pharmacies, and emergency wards, eliminating the necessity for complex, time-consuming lab operations. The technology at the heart of Genomtec ID is the patented Streamlined Nucleic Acid Amplification Technology (SNAAT). This innovation ensures precise pathogen identification within 15 minutes, making it a rapid diagnostic solution. The Genomtec ID system combines the LAMP (loop-mediated isothermal amplification) method with microfluidics and a contactless photonic heating system. This integration allows for simultaneous isolation, purification, concentration, amplification, and detection of specific DNA or RNA fragments of pathogens, significantly speeding up the process while ensuring accuracy on par with or superior to conventional lab-based PCR methods.

One of the standout features of the SNAAT method is its capability for multiplexing, allowing for the simultaneous detection of multiple diagnostic targets on a microfluidic card. This means a single test can identify up to five pathogens at once. The use of a passive microfluidic card, devoid of embedded electronics or electric parts, for nucleic acid isolation, purification, and concentration, not only enhances the detection threshold for target nucleic acids but also reduces the manufacturing costs of disposable reaction cards. The robust diagnostic parameters offered by SNAAT, including sensitivity, specificity, and repeatability, are largely due to its resistance to common inhibitors found in biological samples like blood or drugs. This resistance makes SNAAT an innovative and reliable technology for point-of-care care testing (POCT), promising a new era of convenient and rapid diagnostics accessible to a broader range of healthcare settings.

Related Links:
Genomtec SA


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.